First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.

Markus Moehler,Kohei Shitara,Marcelo Garrido,Pamela Salman,Lin Shen,Lucjan Wyrwicz,Kensei Yamaguchi,Tomasz Skoczylas,Arinilda Campos Bragagnoli,Tianshu Liu,Michael Schenker,Patricio Eduardo Yanez,Mustapha Tehfe,Mingshun Li,Dana Cullen,Arteid Memaj,Ming Lei,H. Xiao,Yelena Y. Janjigian,Jaffer A. Ajani

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.

2021

4002Background: CheckMate 649 is the largest randomized, global phase 3 study of 1L programmed death (PD)-1 inhibitor–based therapy in GC/GEJC/EAC. 1L NIVO + chemo demonstrated superior overall sur...

Keywords:

Checkmate
first line
Cancer
Chemotherapy
Oncology
Nivolumab
Gastroesophageal Junction
Medicine
Internal medicine
Phases of clinical research
esophageal adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations